Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 12, 2007

Korea’s NIH Initiates Genome-Wide Association Study

  • Republic of Korea's NIH (KNIH) and Center for Disease Control and Prevention will use the Affymetrix Genome-Wide Human SNP Array 5.0 for the Korean Association REsource (KARE) project. This genome-wide association study is designed to identify the genetic causes of lifestyle-related complex diseases that are prevalent in Korea.

    "Using the new Affymetrix SNP Array 5.0, we will be able to perform a true, unbiased genome-wide association study," notes Bermseok Oh, Ph.D., chief, division of structural and functional genomics at KNIH.

    The KARE project will use the Affymetrix tool to generate individual genotypes from more than 10,000 human DNA samples. The resulting information will be made available as part of a database to aid dditional research projects. The program will use samples from the prospective epidemiological Ansan and Ansung cohorts in Korea.

    The Affymetrix microarrays will be run in the high-throughput lab of DNA Link, an Affymetrix-certified service provider in Korea. SeouLin Bioscience will also provide technical support to the KNIH.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »